Navigation Links
Cell Therapeutics Exercises Its Option to Sell Interest in Zevalin Joint Venture to Spectrum Pharmaceuticals for $18 Million
Date:2/20/2009

CTI to focus on Pixantrone and OPAXIO Approval and Commercialization

SEATTLE, Feb. 20 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that it exercised its option to sell its 50% ownership interest in the Zevalin joint venture to Spectrum Pharmaceuticals, Inc. (Spectrum) for $18 million. CTI and Spectrum established a joint venture in December 2008 to develop and commercialize Zevalin. At that time CTI contributed all of the Zevalin related assets to the joint venture and sold to Spectrum a 50% membership interest in the joint venture for $15 million, plus certain milestone payments.

The Company will focus its resources on the approval of pixantrone for relapsed aggressive non-Hodgkin's lymphoma (NHL) and OPAXIO for non-small cell lung and ovarian cancer. CTI estimates that as a result of the sale of the Zevalin interest it will reduce expenses by approximately $15 million annually from activities previously associated with Zevalin while providing CTI with non-dilutive source of operating capital.

"CTI continues to believe in the value of Zevalin as a commercially attractive product and effective form of cancer therapy; however, with the impressive clinical trial results for pixantrone and given the company's need for operating capital, we are compelled to exercise our option and focus our resources on pixantrone," noted James Bianco, MD, CEO of CTI. "CTI has been proud to have provided Zevalin to patients since we acquired it in December, 2007 and having the foresight to bring the first line consolidation for indolent NHL data to the FDA for potential label expansion in the front line consolidation setting. With the progress we made in removing many of the barriers that prevent its more widespread use, we are confident Spectrum will be able to ultimately make Zevalin a commercially attractive product."

At the closing of the sale of CTI's 50% m
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... Vestiage, Inc. (stock symbol "VEST") a publicly ... and development, sales and marketing of premium branded ... that it is awarding exclusive Vestiage territories in ... Skin Illuminating Facial Care. Qualified applicants can request ... email to info(at)vestiageinc(dot)com and putting RELUMA in the ...
(Date:5/23/2013)... Colo. , May 23, 2013 Venaxis, ... diagnostic company focused on obtaining FDA clearance and commercializing ... today announced the pricing of an underwritten public offering ... warrants to purchase 3,500,000 shares of its common stock ... a combined public offering price of $1.25 per share ...
(Date:5/23/2013)... Patheon Inc ., a leading provider of contract development ... host a complimentary webinar on “Cleaning Validation: Science, Risk ... 2013 at 11 a.m. Eastern Standard Time. , ... for cleaning validation. Many companies have incorporated their ... of risk. Some companies have chosen to avoid ...
(Date:5/23/2013)... Auburn, MA (PRWEB) May 23, 2013 ... one inch wide and provide 15 mm travel ... nanometers. The small dimensions make these new ... in confined spaces. A vacuum rated version is ... Datasheet:, Drawings, specifications and datasheets can be found ...
Breaking Biology Technology:Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 2Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 3Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 4Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 5Venaxis Announces Pricing of Offering of Common Stock and Warrants 2Venaxis Announces Pricing of Offering of Common Stock and Warrants 3Patheon to Present on “Cleaning Validation: Science, Risk and Novel Approaches to Testing” 2Precision Positioning System Uses Miniaturezed Piezo Linear Motor: LPS-24 Linear Stage by PI 2
... 15 CMS, Inc., an Elekta Company and,worldwide ... today announced the commercial launch of its new ... the Focal product line that also includes FocalSim ... support the,visualization and utilization of 4D image sets ...
... 15 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex:,SVA), a ... the,initiation of clinical trials in Ukraine for its ... trials are being conducted by,Biolik Biopharmaceutical Company, a ... approval in the Country. Biolik will,also market and ...
... Thriving Student ... MARIETTA, Ga., Sept. 15 Solvay Pharmaceuticals, Inc.,has ... fibrosis (CF) through its SolvayCARES Scholarship program. Each,student has ... education. This fall, one SolvayCARES Scholarship winner,will go on ...
Cached Biology Technology:CMS, Inc., an Elekta Company, Announces Commercial Availability of Focal4D(TM) 2Sinovac Initiates Clinical Trials for Inactivated Hepatitis A Vaccine in Ukraine 2Sinovac Initiates Clinical Trials for Inactivated Hepatitis A Vaccine in Ukraine 340 High-Achieving Students with Cystic Fibrosis Receive $100,000 Total in Higher Education Scholarships From SolvayCARES(SM) 240 High-Achieving Students with Cystic Fibrosis Receive $100,000 Total in Higher Education Scholarships From SolvayCARES(SM) 340 High-Achieving Students with Cystic Fibrosis Receive $100,000 Total in Higher Education Scholarships From SolvayCARES(SM) 4
(Date:5/23/2013)... Pacific Northwest National Laboratory honored more than ... of intellectual property at PNNL,s annual Intellectual Property ... The Department of Energy national laboratory named materials ... his work developing battery materials that can store ... electrical grid, and reduce the time it takes ...
(Date:5/23/2013)... new mechanism by which estrogen suppresses lipid synthesis in ... new approach toward treating certain liver diseases. , ... they are changing long-held views in the field. Study ... journal Science Signaling . , "The dogma in ... that only receptors located in the nucleus respond to ...
(Date:5/23/2013)... or harsh treatments because science fails to identify ... the disease. Researchers at Case Western Reserve University ... that allows patients to safely choose to do ... drastic measures. , The project is one of ... engineering at Case Western Reserve and director of ...
Breaking Biology News(10 mins):PNNL staff recognized for scientific accomplishments, moving technologies into the marketplace 2UCI study reveals new mechanism for estrogen suppression of liver lipid synthesis 2Using big data to identify prostate cancers and best treatments 2Using big data to identify prostate cancers and best treatments 3
... As dog bites become an increasingly major public health concern, a ... bites, that the culprits are usually family pets and if they ... more brutal than the first. The study, the largest of ... of Colorado School of Medicine, who found that dogs usually target ...
... available in Spanish . , U.S. Department of ... improve soil on degraded land so it can be used ... Agricultural Research Service (ARS) at the agency,s Appalachian Farming Systems ... replacement subsoils and topsoils to build better and less-costly sports ...
... Meeting on Acoustics -- a major international acoustics conference ... Coral Beach Hotel in Cancun, Mexico. Reporters are invited ... http://www.acoustics.org/press The press room contains news releases ... more than a thousand presentations at the meeting, which ...
Cached Biology News:Study shows young, unsupervised children most at risk for dog bites 2Improving soil for better lawns and gardens 2Worldwide press room opens for major acoustical science and technology conference, Nov. 15-19 2Worldwide press room opens for major acoustical science and technology conference, Nov. 15-19 3Worldwide press room opens for major acoustical science and technology conference, Nov. 15-19 4Worldwide press room opens for major acoustical science and technology conference, Nov. 15-19 5
... gun optimization kit provides a variety of ... particle delivery with the Helios gene gun. ... 0.6 micrometer, 1.0 micrometer, and 1.6 micrometer ... kit, that provides 0.5 g polyvinylpyrrolidone (PVP) ...
... of Gene Expression (SAGE) is a ... offers a cost-effective outsourcing solution for ... libraries. Agencourt's SAGE sequencing service provides ... and long Phred20 read lengths (40 ...
... process of determining the nucleotide sequence of ... is based on Sangers enzymatic method with ... sequencing reactions. The resulting fluorescent products are ... controlled by a computer and the Data ...
... maintenance, calibration, and validation (MCV) ... plate used for hands-free startup, ... using the Bio-Plex suspension array ... for use with Bio-Plex Manager ...
Biology Products: